Former Australian opener Matthew Hayden admitted hostile cricket rivalry between India and Pakistan is unmatched and will test the two teams when they play a high voltage game in the Twenty20 World Cup in Dubai on Sunday.
Hayden is serving a short stint as Pakistan's batting consultant and transferring his vast experience on how to tackle pressure in as intense a rivalry as the Ashes between Australia and England.
"For Australia, England is their old guard as they would say, as at various stages we have been ruled by the Kingdom of the UK and cricket wouldn't be on our shores if it hadn't been the case," Hayden told a virtual media conference.
"But nothing also, that I have ever seen throughout various elements of the game that I have been part of, ever matches the rivalry between India and Pakistan."
The 49-year-old left-hander played 103 Tests for Australia, 20 of them in the Ashes, scoring 1461 runs.
Hayden accepts there is enormous pressure of an India-Pakistan match, often resulting in bitter public reaction for the losing side.
"There is an obvious pressure of an Indo-Pak match, as there is obvious pressure if you play against England if you are an Australian, but the pressure is only what you allow it to be.
"It's a history-making opportunity. We can present all the stats, homework and research and nothing can replace what will be the state, what we dream about, write about and coach about, which will be the event itself."
After the eight-team qualifying rounds, the Super 12 stage starts from Saturday.
Hayden, who joined the Pakistan team last week, said players were in a good place.
"The mood is high, the relationships within the team are very strong and the players seem very happy and relaxed in spite of the obvious pressure starting from our first match."
Hayden, part of the commentary team during the Indian Premier League which finished last week in the United Arab Emirates, singled out KL Rahul and Rishab Pant as the men that Pakistan need to be watch.
"I sense that KL Rahul is a major threat to Pakistan. His dominance in the shorter format is good. Someone like Rishab Pant, with a cheeky smile and his brash nature and beautiful vision for the game, is a destroyer."
Hayden believes Pakistan skipper Babar Azam will be under extra pressure.
"Babar is our premier player and will be targeted and as Chris Gayle (West Indian great) says 'everyone wants to put him in his pocket'.
"There is going to be additional pressure on Babar as captain and as batsman.
"It's a real dog fight and the conditions and margin of error are very little and so good leadership is going to be the key and Babar commands that role and he needs to fulfill that role."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.